The Department of Pathology and Laboratory Medicine (DPLM) provides diagnostic support to the clinical staff of King Faisal Specialist Hospital and Research Centre, a tertiary referral hospital that specialises in transplant and oncology in Saudi Arabia. With a 7% increase each year in testing volume with a fixed budget, it was time to review testing demand and to design strategies to protect limited resources. This article is the report of a pilot test of using "lock-out intervals" (time-based restrictions on the ordering certain tests) as an approach to manage demand. This approach was piloted with a set of tests from the chemistry, haematology, microbiology and cytogenetics sections of the laboratory.

Our premise is that demand management and test optimization are essential elements of a high performing laboratory culture. The literature shows that a plethora of initiatives and strategies have been explored to manage demand. These have included but are not limited to:

-   Reducing or removing reimbursement for some tests,[@b1-asm-4-299]

-   Changing the format of laboratory tests to affect physicians behavior,[@b2-asm-4-299]

-   Enhanced use of IT solutions and clinical support tools,[@b3-asm-4-299]

-   Sharing knowledge by communicating requesting patterns and practices.[@b4-asm-4-299],[@b5-asm-4-299]

The computer software in use in our hospital is Cerner Millennium, (Kansas City, MO, United States) which had not been configured for lock-out intervals for laboratory orderable tests. Therefore, we established a taskforce to explore the extent to which the system could be configured since this would be key to the implementation of a demand management strategy. Cerner Millennium can be configured with selective rules; however, this requires extensive computer programming and language skills, making rules difficult to build and maintain. As an alternative to reconfiguring rules, parameters can be set to check for order duplication; at the catalog type, activity type or orderable level. These parameters can either warn end users of order proximity, or reject an order entry if a new order collection data/time is "too close in time" to a completed order (for the same test), or future scheduled orders. Parameters can be independently set based on inpatient or outpatient settings and are much easier to build and maintain in comparison to rules. We worked with all relevant stakeholders to ensure alignment and to minimize issues once we went live with the lock-outs.

METHODS
=======

Demand management and demand optimization strategies require a multi-faceted approach with buy-in of all stakeholders to ensure success. To that end, we established a task force that comprised members from the laboratory, medical specialties and administration to explore how to optimise services. After many months of focused literature review, scrutiny of our work volumes and growth rates (including perceived areas of overuse), we commenced an initiative to curb inappropriate demand by restricting certain tests within a repeat time window (a lock-out interval or implementation of time-based restrictions on the ordering certain tests). A review of the literature was undertaken and the testing frequencies recommended were compared to the local practices at our hospital. For the pilot implementation of lock-out tests, we chose tests that were: 1) high cost (such as BCR/ABL1 FISH), high volume (complete blood count) or considered overused and/or abused based on information in the literature (ESR, ova and parasite screening).

Data was extracted from the laboratory information system on 19 common tests, to compare before and after implementation of the time-based restrictions. For the purpose of this study, panels of tests were counted as one test. For example, the electrolyte panel contains five tests (sodium, potassium, chloride, creatinine and urea); this panel was counted as one test. The data was captured for the first 6 months of 2016 and 2017 (1 January to 30 June). The list of proposed tests and their minimal repeat intervals were presented to committees and appropriate internal forums to engage colleagues and to ensure that there was internal alignment. Due to the complexity of cases seen at this tertiary referral centre, it was important to ensure that there was medical agreement on the test frequencies, and that there was a common understanding of the medical value of the tests. The final list of tests was approved by the medical and clinical affairs administrators and a date was set to go live. As this was the first time that such an approach had been taken at this institution, it was imperative to engage all stakeholders. To that end, we worked closely with colleagues in the Health Informatics and Technology Affairs (HITA) to ensure robust validation of the new rules and to collaboratively create a newsletter to go to all clinical staff within the hospital. For technical reasons, we were not able to lock-out six of the tests (because there was a potential for a valid request to come from multiple sites such as wound swabs --- and to lock-out the test would have restricted clinically valid tests). The tests selected for lock out were:

-   5 hematology (CBC, ESR, haemoglobin electrophoresis, PT and PTT)

-   6 microbiology (ova and parasites, CMV antigenemia by direct IFA, genital culture, respiratory culture and Gram stain, stool culture, viral acute diarrheal enzyme Immunoassay)

-   1 chemistry (electrolyte profile)

-   1 cytogenetics (BCR/ABL1 fluorescent in situ hybridization)

A safeguard was built into the pilot so that if a lock-out had to be removed for a clinical reason, a process was established to do this within 15 minutes. It was agreed that if a lock-out restriction were taken down for the purpose of the pilot study that it would not be reinstated. The process to unlock a test required the requesting physician to contact the DPLM medical section head to discuss the case. If approved by the section head, the lock-out interval would then be lifted by calling and requesting the change to be performed in the system by HITA staff. By implementing this process, it meant that we were able to minimise and mitigate any potential negative impact should the frequency of testing not support our patient population. We wished to ensure that our approach was conservative, met clinically justified needs and supported the ethos of 'the right test on the right patient at the right time'.

One of the key outcome measures were the testing patterns and frequencies of the tests both both before and after the lock-outs were implemented. This would allow for measurement of both the impact of these changes and associated cost reductions. To that end, data was captured on test numbers before and after lock-outs along with the reference laboratory cost of these tests. The department concurrently implemented a robust plan to systematically validate, using activity-based costing principles, i.e., the current DPLM cost to deliver the tests that were part of this pilot.

RESULTS
=======

The laboratory has experienced a 7% year over year organic growth ([Figure 1](#f1-asm-4-299){ref-type="fig"}). We forecast that by the end of 2017 we will have produced 17.9 million test results across the 18 sections within the DPLM, which is manned by approximately 500 staff (comprised predominantly of medical staff, medical technologists, technicians and phlebotomists). The growth differential experienced across the sections ranged from anatomic pathology with flat growth (0.3%) versus molecular genetics growing by 58% (highest growth rate). The initial pilot focused on 19 tests from the biochemistry, hematology, microbiology and cytogenetics sections that were selected for lock-out based on our literature review. From these 19 proposed tests, 13 tests and panels were implemented as lock-outs ([Table 1](#t1-asm-4-299){ref-type="table"}). To compare the increase in tests that were restricted to those that were not, data was captured from 2016 (before the lock-outs were implemented) and 2017. The locked-out tests reduced the number of tests by an overall average of 6.6% versus the previous year ([Table 2](#t2-asm-4-299){ref-type="table"}), and saved 2.03 million Saudi Arabian Riyals (SAR) during the 6-month period.

The reduction in testing volumes ranged from 0.2% to 70.3% ([Figure 2](#f2-asm-4-299){ref-type="fig"}) and based on total test numbers this represented an overall reduction in testing volume for the 6 months of 6.6%, while other tests, not restricted, grew overall by 7%. This means that the testing volume reduced by approximately 13% in real terms for all tests. The cost saved in hematology was 1.4 million SAR over a 6-month period ([Table 2](#t2-asm-4-299){ref-type="table"}), with an overall reduction of 6.2% in testing volume. The cost saved in microbiology was 0.36 million SAR over a 6-month period, with an overall reduction of 11.7% in testing volume.

DISCUSSION
==========

Our premise is that demand management and test optimization are essential elements of a high performing laboratory culture. We have a duty to ensure that the right tests are performed on the right patients at the right time to drive optimal outcomes. Published reports state that 20% to 50% of laboratory testing may not be appropriate (not clinically relevant nor supported by evidence based practice[@b1-asm-4-299]--[@b14-asm-4-299]). Our hospital is transforming to a new not-for-profit commercial entity and the DPLM was tasked with ensuring the appropriateness (clinical utility) of testing.

In our review of the literature, we initially focused on tests that were high volume, high cost or perceived to be overused at our hospital. In comparison with other institutions, our organic growth rate (7% year on year) was similar (others reported increases of 5 to 10% year on year[@b8-asm-4-299]). Rao et al[@b8-asm-4-299] described three developments that are positioning providers to rationalize the services that they provide by 1) increasing computer links for requesting tests and reviewing results, 2) allowing evidence-based medicine to drive a willingness to review testing, and 3) greater recognition of the importance of multidisciplinary teams working towards the development of care pathways.

Our experience indicates that these developments are necessary to implement demand optimization, but in addition we would add 1) engagement of all relevant stakeholders, including executive sponsorship to drive the initiative forwards, 2) optimize test requests using rules and algorithms that are IT-based, and 3) reinforcing the coaching and value-added service that pathologists are able to provide by training (and re-training) users on the appropriateness of testing.

Toolkits have been created for demand management that to seek to reduce inappropriate testing,[@b9-asm-4-299] but the widespread uptake of these strategic approaches is not evident. The landscape of inappropriate utilization varies by clinical setting with some over 21% and some under by 45%.[@b10-asm-4-299] The focus of our pilot study was to understand the impact of overutilization of tests. Our results demonstrate a reduction in testing volume of 24 905 tests during a 6-month period. A large medical laboratory in the US described saving US\$2 million over a 3 year period (7.5 million SAR) by implementing time-based rules.[@b11-asm-4-299] Our experience, with a limited pilot program has saved 2.03 million SAR in a 6-month period (over 4 million SAR projected annually). Others have achieved better financial improvements,[@b12-asm-4-299] but nonetheless, they demonstrated management of test ordering by means of frequency filters. The impact of the lock-outs in our experience varied; for example, the reduction in inappropriate testing in hematology was 6.21%, saving 1.38 million SAR, while in microbiology, the testing was reduced by 11.7% but the savings was less (0.36 million SAR). This approach is limited in that it may not be applicable to all laboratory tests; however, the success of this pilot study would encourage a more widespread use of this methodology where applicable.

There is broad agreement on the benefits from optimizing laboratory tests,[@b13-asm-4-299] but few authors have looked at the patient impact[@b14-asm-4-299] and population level studies.[@b15-asm-4-299] We are of the opinion that this is an area of healthcare delivery that needs to be thoroughly explored with sharing of best practices. The lack of continuous education is cited as one of the drivers for inappropriate testing[@b16-asm-4-299]--[@b19-asm-4-299] and our experience suggests that robust demand management requires strong medical leadership, coaching and education. The concept of locking-out tests has been well received by hospital administration, but had some initial resistance from clinicians. However, after personal communication with senior clinicians involved in the process along with a hospitalwide newsletter describing the rationale for the lock-outs this resistance soon disappeared. There is a demonstrable reduction in work volume with associated cost avoidance; importantly, this will reduce the number of blood samples collected from patients that add no clinical value. Minimal re-test intervals using computer-based rules are effective in supporting strategies to manage demand. Due to the success of this pilot study, we will continue to develop and add more tests to create more minimal retest interval rules in the computer system to manage demand and ensure that we use our resources wisely.
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###### 

Thirteen laboratory tests chosen for the pilot study.

  Test name                                                               Minimal re-test interval
  ----------------------------------------------------------------------- -----------------------------------------------------------
  CMV antigenemia, direct IFA                                             Every 72 hours
  Stool culture                                                           Every 72 hours
  Ova and parasites                                                       Once a week/not from inpatients after 3 days of admission
  CBC                                                                     Every 2 hours
  PT                                                                      Every 4 hours
  Gram stain (genital) and culture                                        Once a week
  Biochemistry profile[@b6-asm-4-299]                                     Every 2 hours
  Respiratory culture and gram stain                                      Every 72 hours
  Viral acute diarrheal EIA                                               Once a week
  BCR-ABL1[a](#tfn1-asm-4-299){ref-type="table-fn"} FISH[@b7-asm-4-299]   Every 3 months
  Hb electrophoresis                                                      Every 6 months
  PTT                                                                     Every 4 hours
  ESR                                                                     Daily

Philadelphia chromosome;

CMV: cytomegalovirus, IFA: indirect immunofluorescence assay, CBC: complete blood count, PT: prothrombin time; PTT: partial thromboplastin time, EIA: enzyme immunoassay, FISH: fluorescent in situ hybridization, ESR: erythrocyte sedimentation rate.

###### 

Numbers of tests and costs before and after implementing a minimum retest interval.

  Test name                            2016 number of tests   2017 number of tests   Percentage difference   2016 cost (in SAR)   2017 cost (in SAR)   Difference in cost (SAR)
  ------------------------------------ ---------------------- ---------------------- ----------------------- -------------------- -------------------- --------------------------
  BCR/ABL1 for t(9;22), FISH           352                    268                    23.9                    594 880              452 920              141 960
  CBC                                  198 890                186 733                6.1                     9 944 500            9 336 650            607 850
  CMV antigenemia, direct IFA          2954                   2433                   17.6                    1 255 450            1 034 025            221 425
  Electrolyte profile                  1805                   1057                   41.1                    351 975              206 115              145 860
  ESR                                  15 121                 12 850                 15.0                    2 268 150            1 927 500            340 650
  Genital culture                      800                    756                    5.5                     140 000              132 300              7700
  Hemoglobin electrophoresis           1989                   1915                   3.7                     618 579              595 565              23 014
  Ova and parasites                    1776                   1484                   16.4                    310 800              259 700              51 100
  PT                                   74 656                 74 507                 0.2                     3 732 800            3 725 350            7450
  PTT                                  74 377                 66 350                 10.8                    3 718 850            3 317 500            401 350
  Respiratory culture and gram stain   3860                   3668                   5.00                    598 300              568 540              29 760
  Stool culture                        2464                   2163                   12.2                    300 608              263 886              36 722
  Viral acute diarrheal EIA            64                     19                     70.3                    20 800               6175                 14 625
  **Total**                            **379 108**            **35 4203**            **6.6**                 **23 855 692**       **21 826 226**       **2 029 466**
